(Press-News.org) A drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukaemias and non-Hodgkin lymphomas in clinical trials later this year.
Targeted drugs made from engineered immune proteins - called monoclonal antibodies - have revolutionised treatment for several types of cancer in recent years. They work by sticking to specific proteins found on the surface of cancer cells, flagging them up to be killed by the immune system. Unfortunately, a number of patients do not respond or develop resistance to treatment.
Groundbreaking findings, published online today (13 April 2015) in the prestigious journal Cancer Cell, show that resistance to many types of antibody drugs can be overcome by preventing cancer cells from 'hiding' from immune cells. The research was carried out by scientists at the University of Southampton and the Swedish biotech company, BioInvent International.
The researchers, who were funded by Leukaemia & Lymphoma Research and Cancer Research UK, have shown that some cancer cells are able to draw monoclonal antibodies inside themselves, making them invisible to immune cells. However, the researchers showed that a new antibody, called BI-1206, can effectively prevent this drug destruction process and enhance cancer killing by binding to a molecule called FcγRIIB.
BI-1206 showed remarkable success in mice in overcoming resistance to monoclonal antibodies like rituximab, currently used to treat different types of lymphoma and leukaemia.
The study, led by Dr Ali Roghanian and Professor Mark Cragg in Southampton and Dr Ingrid Teige and Professor Björn Frendéus in Sweden, represents a six year endeavour into how to improve antibody therapeutics for blood cancers.
Professor Cragg said: "With more monoclonal antibody treatments being developed, there is an urgent need to understand how tumours become resistant to them and develop ways to overcome it. Not only does BI-1206 appear to be able to reverse resistance to a range of monoclonal antibodies, it is also effective at directly killing cancer cells itself."
The new drug will now be tested in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma in an early stage clinical trial. The trial will test safety in humans and if it has any anti-cancer effects when combined with rituximab. This is a new collaborative venture between Leukaemia & Lymphoma Research, Cancer Research UK and its development and commercialisation arm Cancer Research Technology, aimed at accelerating the delivery of promising new treatments into blood cancers.
Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: "Targeted drugs, like monoclonal antibodies, have shown great promise in recent years in effectively treating a patient's disease while minimising side effects. BI-1206 could have a real impact on survival for a significant number of patients."
Björn Frendéus, Ph.D., Chief Scientific Officer of BioInvent, and honorary Professor at Southampton University, said: "BI-1206 binds very specifically to the inhibitory FcyRIIB, a receptor that acts as a brake to dampen critical anti-cancer immune cell's function and to eliminate therapeutic antibody from the targeted tumor cell surface."
Emma Smith, senior science information officer at Cancer Research UK, said: "This exciting research has the potential to be a game-changer for people with white blood cell cancers that don't respond, or have stopped responding, to treatments like rituximab. It could also make immunotherapy for other types of cancer more effective too. The work was carried out in mice, so we'll have to wait for the results from clinical trials to find out if the treatment is safe and effective in people, but it's certainly a promising approach and could lead to more potent drug combinations that benefit patients."
INFORMATION:
BOSTON -Placebos have helped to ease symptoms of illness for centuries and have been a fundamental component of clinical research to test new drug therapies for more than 70 years. But why some people respond to placebos and others do not remains under debate.
With the advent of genomics, researchers are learning that placebo responses are modified by a person's genetics, a discovery that raises important new questions regarding the role of the placebo in patient care and in drug development: How many genetic biomarkers exist? Can the medical field harness the placebo ...
This news release is available in Spanish. Through his latest research, Javier Polavieja, a professor Sociology in the Social Sciences Department who holds a UC3M- Santander Named Chair of (Cátedra de Excelencia), has shown how European women who emigrate to other countries within the same continent take the cultural norms of their home countries with them. Those norms are decisive when it comes to determining their work behavior.
To reach this conclusion, the researcher compared the attitudes of over three thousand immigrant women from some twenty European countries ...
This news release is available in French.
Dancing the Argentine tango could have potential benefits for people at certain stages in the development of Parkinson's disease (PD), according to findings in a new study by researchers at the Montreal Neurological Institute and Hospital -The Neuro, McGill University and the Research Institute of the McGill University Health Centre. The study looked at changes in patients' motor abilities following a 12-week tango course, and is also the first study to assess the effect that tango has on non-motor symptoms.
The study looked ...
A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities, according to an article published online by JAMA Internal Medicine.
Nearly 2 million frail elderly Americans live in long-term care facilities and many of them have osteoporosis and bone fracture rates higher than less impaired elderly individuals. A hip fracture can be dire, decreasing mobility, independence and often leading to death, according to background in the study.
Susan L. ...
Pediatric readiness at emergency departments (EDs) throughout the United States appears to have improved based on self-reported online assessments of compliance with national guidelines, according to an article published online by JAMA Pediatrics.
The importance of EDs maintaining a state of readiness to care for children cannot be overemphasized because day-to-day readiness affects disaster planning and response and patient safety. The Emergency Nurses Association joined the American Academy of Pediatrics and the American College of Emergency Physicians in cosponsoring ...
BOSTON - Targeted cancer therapies work by blocking a single oncogenic pathway to halt tumor growth. But because cancerous tumors have the unique ability to activate alternative pathways, they are often able to evade these therapies -- and regrow. Moreover, tumors contain a small portion of cancer stem cells that are believed to be responsible for tumor initiation, metastasis and drug resistance. Thus, eradicating cancer stem cells may be critical for achieving long-lasting remission, but there are no drugs available that specifically attack cancer stem cells.
Now a research ...
Popular North Sea fish such as haddock, plaice and lemon sole could become less common on our menus because they will be constrained to preferred habitat as seas warm, according to a study published today in Nature Climate Change.
Fish distributions are limited by water temperature and some species can only thrive in certain habitats and depths. In the last 40 years the North Sea has warmed four times faster than the global average and further warming is predicted over the coming century, leading fisheries scientists to study how this will impact on commercial species.
The ...
About a quarter of all atrial fibrillation (AF) patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to UCSF researchers, and these providers must be made aware of the resulting potential health risks.
Their research letter appears online and will be in the June 1 issue of JAMA Internal Medicine.
"The irony is that there is a general push to get providers to prescribe these drugs, and they are also generally under-prescribed among many AF patients who actually need them," said senior author Gregory Marcus, ...
MADISON, Wis. - Take a material that is a focus of interest in the quest for advanced solar cells. Discover a "freshman chemistry level" technique for growing that material into high-efficiency, ultra-small lasers. The result, disclosed today [Monday, April 13] in Nature Materials, is a shortcut to lasers that are extremely efficient and able to create many colors of light.
That makes these tiny lasers suitable for miniature optoelectronics, computers and sensors.
"We are working with a class of fascinating materials called organic-inorganic hybrid perovskites that ...
Neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in infants following birth, has historically been associated with illicit drug use among pregnant women.
But a study by a team at Vanderbilt University Medical Center shows that pregnant women are commonly being prescribed opioids -- narcotic pain relievers such as hydrocodone -- which results in an increased likelihood of NAS. In addition, the study found that opioid type and duration of exposure combined with tobacco use or selective serotonin reuptake inhibitor use (for treating depression and anxiety) ...
